Navigation Links
Tailoring glioblastoma therapies: 1 size does not fit all
Date:2/6/2008

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Dr. Bonni's group found that the transcription factor STAT3 has either a tumor promoting or tumor suppressive effect depending upon the genetic profile of the glioblastoma tumor.

Glioblastomas are the most common and aggressive type of adult brain cancer, with an annual incidence of approximately 13,000 in the United States, and an expected median survival rate of just over a year. STAT3 is a cytokine-activated transcription factor that has been previously reported to play a pro-oncogenic role in tumor development. Thus, much effort has been aimed at the development of STAT3 inhibitors as chemotherapeutic agents.

Dr. Bonni and colleagues now report that STAT3 can function as either a tumor suppressor or an oncoprotein. Using a mouse model system of two common genetic mutations in glioblastomas - PTEN deficiency or EGFRvIII activation -- the researchers show that PTEN regulates STAT3 tumor suppressor function, while STAT3 cooperates with the EGFRvIII oncoprotein to promote tumor growth.

Thus, the researchers convincingly demonstrate a need for effective therapies tailored to the unique genetic thumbprint of individual glioblastoma tumors. "These findings may change the way we approach not only glioblastoma but other types of cancer as well", says Azad Bonni, senior author of the study.


'/>"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: